论文部分内容阅读
中国医药行业经历了2006年的冬天后迅速回暖,表面上是经济规律使然,实际上是近年来医疗体制、市场准入、监管、创新激励几个核心政策的一系列改革起到了推波助澜的作用,而“行业政策”这只无形的推手甚至还将主导医药行业未来发展的方向。
In fact, the pharmaceutical industry in China experienced a rapid pick-up after the winter of 2006, apparently due to economic rules. In fact, it has actually played a role in fueling a series of reforms in several core policies of the medical system, market access, supervision and innovation incentives in recent years. The “industry policy” this invisible promoter will even dominate the future direction of the pharmaceutical industry.